EDITORIAL

661 Hepatitis C virus eradication in people living with human immunodeficiency virus: Where are we now?
Spera AM, Pagliano P, Conti V

667 Hepatic pseudotumor: A diagnostic challenge
Samanta A, Sen Sarma M

671 Liver disease in patients with transfusion-dependent β-thalassemia: The emerging role of metabolism dysfunction-associated steatotic liver disease
Fragkou N, Vlachaki E, Goulis I, Sinakos E

678 Fecal microbiota transplantation in the treatment of hepatic encephalopathy: A perspective
Samanta A, Sen Sarma M

684 Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet?
Lee HD, Yuan LY

REVIEW

688 Multifunctional role of oral bacteria in the progression of non-alcoholic fatty liver disease
Mei EH, Yao C, Chen YN, Nan SX, Qi SC

703 Unraveling the relationship between histone methylation and nonalcoholic fatty liver disease
Xu L, Fan YH, Zhang XJ, Bai L

716 Genetic screening of liver cancer: State of the art
Peruhova M, Banova-Chakarova S, Miteva DG, Velikova T

731 Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges
Xie C, Alkhouri N, Elfeki MA

MINIREVIEWS

751 Current concepts in the management of non-cirrhotic non-malignant portal vein thrombosis
Willington AJ, Tripathi D

766 Combined hepatocellular cholangiocarcinoma: A clinicopathological update
Vij M, Veerankutty FH, Rammohan A, Rela M

776 Microbiota treatment of functional constipation: Current status and future prospects
Li Y, Zhang XH, Wang ZK
ORIGINAL ARTICLE

Case Control Study

784 Outcomes of endoscopic submucosal dissection in cirrhotic patients: First American cohort
Pecha RL, Ayoub F, Patel A, Muftah A, Wright MW, Khalaf MA, Othman MO

Retrospective Cohort Study

791 Characteristics of patients with Wilson disease in the United States: An insurance claims database study
Daniel-Robin T, Kumar P, Benichou B, Combal JP

800 Quantifying the natural growth rate of hepatocellular carcinoma: A real-world retrospective study in southwestern China
Tu L, Xie H, Li Q, Lei PG, Zhao PL, Yang F, Gong C, Yao YL, Zhou S

Prospective Study

809 Characterization of acute-on-chronic liver diseases: A multicenter prospective cohort study

822 Presepsin as a biomarker of bacterial translocation and an indicator for the prescription of probiotics in cirrhosis

Basic Study

832 Ornithine aspartate effects on bacterial composition and metabolic pathways in a rat model of steatotic liver disease
Lange EC, Rampelotto PH, Longo L, de Freitas LBR, Uribe-Cruz C, Alvareza-da-Silva MR

SYSTEMATIC REVIEWS

843 Genetic diversity and occult hepatitis B infection in Africa: A comprehensive review

LETTER TO THE EDITOR

860 Gestational diabetes mellitus may predispose to metabolic dysfunction-associated steatotic liver disease
Milionis C, Ilias I, Koukkou E
ABOUT COVER
Peer Reviewer of World Journal of Hepatology, Raquel Rocha, MD, Associate Professor, Department of Sciences of Nutrition, School of Nutrition, Federal University of Bahia, Salvador 41701-035, BA, Brazil. raquelrocha2@yahoo.com.br

AIMS AND SCOPE
The primary aim of World Journal of Hepatology (WJH, World J Hepatol) is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJH mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

INDEXING/ABSTRACTING
The WJH is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (ESCI), Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJH as 2.4.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yi-Xuan Cai; Production Department Director: Xiang Li; Cover Editor: Xiang Li.

NAME OF JOURNAL
World Journal of Hepatology

ISSN
ISSN 1948-5182 (online)

LAUNCH DATE
October 31, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Nikolaos Pyrsopoulos, Ke-Qin Hu, Koo Jeong Kang

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF
Shuang-Suo Dang

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
May 27, 2024

COPYRIGHT
© 2024 Baishideng Publishing Group Inc

PUBLISHING PARTNER
Department of Infectious Diseases, the Second Affiliated Hospital of Xi’an Jiaotong University

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/lpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/lpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/lpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/lpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/lpg/gerinfo/208

POLICY OF CO-AUTHORS
https://www.wjgnet.com/lpg/gerinfo/310

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/lpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/lpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

PUBLISHING PARTNER’s OFFICIAL WEBSITE
http://2yuan.xjtu.edu.cn/Html/Departments/Main/Index_21148.html
Basic Study

Ornithine aspartate effects on bacterial composition and metabolic pathways in a rat model of steatotic liver disease

Elisa Carolina Lange, Pabulo Henrique Rampelotto, Larisse Longo, Laura Bainy Rodrigues de Freitas, Carolina Uribe-Cruz, Mario Reis Alvares-da-Silva

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer review report’s scientific quality classification

Grade A (Excellent): A
Grade B (Very good): 0
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Liu J, China

Received: December 11, 2023
Peer review started: December 11, 2023
First decision: January 25, 2024
Revised: February 2, 2024
Accepted: March 5, 2024
Article in press: March 5, 2024
Published online: May 27, 2024

Abstract

BACKGROUND
Metabolic-dysfunction associated steatotic liver disease (MASLD) is a hepatic manifestation of metabolic syndrome. Studies suggest ornithine aspartate (LOLA) as drug therapy.

AIM
To analyze the influence of LOLA intake on gut microbiota using a nutritional
model of MASLD.

**METHODS**

Adult male Sprague Dawley rats were randomized into three groups: Control (10 rats fed with a standard diet), MASLD (10 rats fed with a high-fat and choline-deficient diet), and LOLA (10 rats receiving 200 mg/kg/d LOLA, after the 16th week receiving high-fat and choline-deficient diet). After 28 wk of the experiment, animals were euthanized, and feces present in the intestine were collected. Following fecal DNA extraction, the V4 region of the 16S rRNA gene was amplified followed by sequencing in an Ion S5™ system.

**RESULTS**

Alpha and beta diversity metrics were comparable between MASLD and LOLA. 3 OTUs were differentially abundant between MASLD and LOLA, which belong to the species *Helicobacter rodentium*, *Parabacteroides goldsteinii*, and *Parabacteroides distasonis*. The functional prediction provided two different metabolic profiles between MASLD and LOLA. The 9 pathways differentially abundant in MASLD are related to a change in energy source, adenosine/purine nucleotides degradation as well as guanosine and adenosine deoxyribonucleotides biosynthesis. The 14 pathways differentially abundant in LOLA are associated with four major metabolic functions primarily influenced by L-aspartate, including tricarboxylic acid cycle pathways, purine/guanosine nucleotides biosynthesis, pyrimidine ribonucleotides biosynthesis and salvage as well as lipid IVA biosynthesis.

**CONCLUSION**

Although LOLA had no influence on alpha and beta diversity in this nutritional model of MASLD, it was associated with changes in specific gut microbes and their related metabolic pathways.

**Key Words:** Animal model; Gut microbiota; Metabolic-associated steatotic liver disease; Metabolic prediction; Ornithine aspartate

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** In this nutritional model of metabolic dysfunction-associated steatotic liver disease, ornithine aspartate administration did not exhibit any impact on the alpha and beta diversity of the gut microbiota. Nonetheless, notable distinctions were noted among the cohorts concerning *Parabacteroides goldsteinii* and *Parabacteroides distasonis*, both of which pose as promising prospects for advanced probiotics owing to their advantageous implications in mitigating inflammation and addressing obesity. The variances observed in bacterial composition and metabolic profiles were directly associated with the presence of L-aspartate.

**Citation:** Lange EC, Rampelotto PH, Longo L, de Freitas LBR, Uribe-Cruz C, Alvares-da-Silva MR. Ornithine aspartate effects on bacterial composition and metabolic pathways in a rat model of steatotic liver disease. *World J Hepatol* 2024; 16(5): 832-842

**URL:** https://www.wjgnet.com/1948-5182/full/v16/i5/832.htm

**DOI:** https://dx.doi.org/10.4254/wjh.v16.i5.832

**INTRODUCTION**

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a general term for a hepatic manifestation of metabolic syndrome, with a complex pathophysiology. The disease is usually silent and asymptomatic, manifesting in more advanced and irreversible stages of liver damage[1,2].

Currently, there is no specific drug therapy approved for MASLD. Several studies are investigating promising drugs, like peroxisome proliferator-activated receptors (PPARs) and glucagon-like peptide 1 (GLP-1) agonists[3] and have recently been suggested that ornithine aspartate (LOLA) can be useful[4]. LOLA improves the capacity of the circulating ammonia reduction system through the dissociation and absorption of its amino acids[5]. The relationship between gut microbiota and amino acids occurs in a bidirectional way; while bacteria play a role in the metabolism and synthesis of amino acids, amino acids contribute to survival and homeostasis of the microbiota[6,7]. In addition, due to the close relationship between the gut and liver, dysbiosis (i.e., the imbalance of the gut microbiota) has been linked to the progression of MASLD, and a large body of evidence suggests that microbiota modulation may be an important target in the treatment of MASLD[8].

Here, we further explored the influence of LOLA intake on the gut microbiota and related metabolic pathways using an experimental model of MASLD, providing evidence on the molecular mechanisms of how LOLA induces changes in probiotic microbes and their metabolism.
MATERIALS AND METHODS

Animals
Thirty adult (60 d old) male Sprague Dawley rats were used. The animals were randomized by weight, and two rats were housed in each polypropylene cage with sawdust-covered floors. They were kept in a controlled temperature environment (22 ± 2 °C), and a 12-hour light/dark cycle. The methods can be accessed in detail in the article recently published by the group[9].

Study design
The animals were randomized into three groups, control (10 rats fed with a standard diet), MASLD (10 rats fed with a high-fat and choline-deficient diet; HFCD), and LOLA (10 rats receiving 200 mg/kg/d LOLA, after the 16th week receiving HFCD diet)[9-11]. The animals in the control and MASLD groups were weighed weekly throughout the experiment to track body weight, whereas those in the LOLA group were initially weighed weekly until week 16 and then twice a week thereafter to facilitate adjustments in LOLA doses. After 28 wk of the experiment, all animals were euthanized. The livers were collected aseptically, and their weights were measured. This biological material was stored for the quantitative assessment of fat deposits, as described below. Additionally, feces present in the intestine were collected aseptically, frozen in liquid nitrogen, and stored in a -80°C freezer until the proposed evaluation.

All the animals who received HFCD presented induced MASLD, and no animal died during the experimental period. All experimental procedures were approved by the Ethics Committee for the Use of Animals of Hospital de Clínicas de Porto Alegre (Protocol number: 2020-0037). The procedures for the use of scientific animals were conducted following the Guide for the Care and Use of Laboratory Animals, 8th ed[12].

Quantitative analysis of liver fat deposition
To analyze hepatic lipid content, the previously frozen liver tissue samples were thawed on ice and homogenized in phosphate buffer saline (20 mg of tissue/mL). Using this homogenate, the concentrations of triglycerides, total cholesterol, and total lipid accumulation were evaluated. Hepatic triglycerides and total cholesterol were assayed enzymatically using colorimetry (Labtest Diagnóstica SA, Brazil). The total lipid concentration was determined using the modified protocol of Gómez-Lechón et al[13]. Briefly, liver tissue was homogenized in phosphate buffer saline and incubated with 1 μL of Nile Red solution (1 mg/mL in acetone) at 37 °C for 15 min. Fluorescence was measured at 488 nm excitation and 550 nm emission wavelengths (SpectraMax M3). The values obtained were normalized to the total protein content of the homogenate[14]. The results are expressed as fluorescence/μg protein. All analyses were performed in duplicate.

DNA extraction and 16S rRNA sequencing
The genomic material was obtained from approximately 200 mg of the fecal sample with an appropriate commercial kit (QIAmp DNA Stool Mini kit, Qiagen, Hilden, Germany) following the manufacturer’s instructions. At the end of the DNA extraction, an average of 5-10 μg of genomic material was obtained. The hypervariable V4 region from the rRNA gene was amplified through PCR using genomic DNA (approximately 50 ng per reaction) and the following primer pair: 515F (5’-GTGCCAGCMGCCTGCGGTAA-3’) and 806R (5’-GGACTACHVGGGTWTCTAAT-3’). To pool different samples in the same reaction, we used the primer-fusion method, and each sample had a distinct barcode attached to the corresponding PCR product. The amplification was performed using Platinum™ PCR SuperMix High Fidelity (Invitro-gen, Carlsbad, CA, United States). PCR was conducted under the following conditions: 95 °C for 600 s and thereafter 30 cycles of 95 °C for 30 s, 57 °C for 30 s, and 72 °C for 60 s with a final extension of 72 °C for 60 s. The products were verified through electrophoresis in an agarose gel, purified with AMPure XP PCR Purification Kit (Beckman Coulter, Brea, CA, United States), quantified using Qubit™ dsDNA HS Assay Kit (Invitrogen, Carlsbad, CA, United States), and subjected to emulsion PCR using Ion Chef™ System (Thermo Fisher Scientific, Waltham, MA, United States). After, the resulting enriched beads were sequenced in Ion S5™ System (Thermo Fisher Scientific, Waltham, MA, United States) using Ion 510™ Chip Kit (Thermo Fisher Scientific, Waltham, MA, United States).

Bioinformatics analysis
The sequence data exported from the Ion S5™ System was processed using a custom pipeline in Mothur v.1.47.0[15]. Initially, sequences were depleted of barcodes and primers (where no mismatch was allowed), and then a quality filter was applied to eliminate low-quality reads. Quality control was conducted by trimming the low-quality reads, those with incorrect length, those containing an ambiguous base, or containing homopolymers longer than 6 bp. All potentially chimeric sequences were identified and removed using VSEARCH[16]. In addition, singletons were removed to avoid potentially spurious sequences derived from PCR or sequencing errors.

After these initial quality filtering and trimming steps, the remaining sequences were clustered into operational taxonomic units (OTUs) based on a 99% identity level and were classified against the SILVA v138 reference database at 97% similarity. Sequences that could not be classified (i.e., “unknown” sequences), as well as sequences identified as eukaryotes, mitochondria, and chloroplasts, were removed before further analysis. After all filtering steps, the resulting OTUs table was composed of 754725 sequences, with an average of 27952 sequences per sample. The resulting OTUs table was rarefied to the smallest library size (i.e., 17109). Subsequent analyses of the sequence dataset were performed in R v. 4.0.0 using vegan, phyloseq, ggplot2, and Microbi-omeAnalystR packages.
**Microbial community and statistical analysis**

Alpha diversity was assessed using the number of observed taxa, ACE, and Shannon index. Statistical confidence was accessed using the multivariate Kruskal-Wallis test. For the overall comparison of significant differences among bacterial communities (i.e., beta diversity), principal coordinates analysis (PCoA) was performed. A matrix using the Bray–Curtis dissimilarity metric was calculated for each pair of samples. To achieve statistical confidence for the sample grouping observed by PCoA, the ANOSIM multivariate test was performed on the distance matrix. To compare additional differences among the microbial communities, clustering methods based on Bray–Curtis dissimilarity were performed. The results of hierarchical clustering were visualized using dendrograms. Venn dendrogram was generated using InteractiVenn[17].

To identify differentially abundant taxa at the OTU level, the linear discriminant effect size (Lefse) method was performed[18]. The algorithm performs a nonparametric factorial Kruskal–Wallis sum rank test and linear discriminant analysis (LDA) to determine statistically significant different features among taxa and estimates the effect size of the difference. Differences were considered significant for a logarithmic LDA score threshold of ±2.0 and a P-value < 0.05. To further refine the taxonomic classification of the differentially abundant OTUs down to the species level, we blasted the reference sequence of the OTUs against the NCBI 16S rRNA database by using BLAST.

**Metabolic prediction**

Metabolic pathways were predicted using the OTU sequences (at 99% similarity) and their abundance in PICRUSt2[19]. The functional annotation of PICRUSt2 predictions was obtained based on the MetaCyc database. MetaCyc pathway abundances are calculated in PICRUSt2 through structured mappings of EC gene families to pathways. Differentially abundant pathways were determined using Lefse. Differences were considered significant for a logarithmic LDA score threshold of ±4.0 and a P value < 0.05.

**RESULTS**

The general characteristics of the experimental model developed regarding body weight gains of the rats, liver weight, as well as the concentrations of triglycerides, total cholesterol, and total lipid accumulation in the liver, are available in Table 1.

**Microbial diversity**

The number of observed taxa, ACE, and Shannon indexes were used to compare the alpha diversity among the three groups, i.e., control, MASLD, and LOLA (Figure 1). Significant differences were observed when control was compared to MASLD and LOLA (P = 0.0001, P = 0.0001, and P = 0.005 for observed taxa, ACE, and Shannon, respectively). However, no difference was observed between MASLD and LOLA (P = 0.6, P = 0.9, and P = 0.6 for observed taxa, ACE, and Shannon, respectively).

PCoA analysis and dendrogram clustering (based on the Bray–Curtis metric) was used to determine the clustering of samples and to better understand similarities and differences among the bacterial community structures (Figure 2). Significant differences were observed when control was compared to MASLD and LOLA, which was confirmed by ANOSIM (P = 0.001). However, no difference was observed between MASLD and LOLA groups (ANOSIM, P = 0.1).

**Microbial composition**

**Differentially abundant microbiota:** In total, 22 OTUs were differentially abundant among groups, which belong to 12 genera/families according to the SILVA rRNA database. Among these 22 OTUs, only 3 differed between LOLA and MASLD (Helicobacter rodentium, Parabacteroides goldsteinii, and Parabacteroides distasonis) (Figure 3). The other OTUs showed differential abundance relative to the control group: 10 OTUs increased at MASLD and LOLA (Romboutsia ilealis, Bacteroides vulgatus, Lachnospiraceae_unclassified (2 OTUs), Tyzzerella nexilis, Facalimonas umbilicata, Peptococcaceae uncultured, Blautia pseudococcoides or Blautia luminis, Rufenchibacterium lactatiformans, and Anaerotignum faecicola) (Supplementary Figure 1 and 9) OTUs decreased at MASLD and LOLA (Lactobacillus gasseri, Lachnospiraceae_unclassified, Lachnospiraceae_NK4A136_group (5 OTUs), and Muribaculaceae_ge) (Supplementary Figure 2).

**Metabolic prediction**

The metabolic prediction was calculated using PICRUSt2 and the MetaCyc database. In total, 22 differentially abundant microbial metabolic pathways were identified between MASLD and LOLA (Figure 4).

The 8 pathways differentially abundant in MASLD are related to a change in energy source, adenosine, and purine nucleotides degradation, as well as guanosine and adenosine deoxyribonucleotides biosynthesis. The 14 pathways differentially abundant in LOLA are related to four major metabolic functions, including tricarboxylic acid cycle pathways, nucleotides degradation, as well as guanosine and adenosine deoxyribonucleotides biosynthesis. The 14 pathways differ-

**PCoA analysis and dendrogram clustering (based on the Bray–Curtis metric) was used to determine the clustering of samples and to better understand similarities and differences among the bacterial community structures (Figure 2). Significant differences were observed when control was compared to MASLD and LOLA, which was confirmed by ANOSIM (P = 0.001). However, no difference was observed between MASLD and LOLA groups (ANOSIM, P = 0.1).**
### Table 1 General characteristics of the nutritional model of metabolic-dysfunction associated steatotic liver disease

<table>
<thead>
<tr>
<th>Variables</th>
<th>Control</th>
<th>MASLD</th>
<th>LOLA</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td>180.9 ± 37.4a</td>
<td>325.1 ± 92.2c</td>
<td>310 ± 56.1c</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Fresh liver weight (g)</td>
<td>17.2 ± 2.4a</td>
<td>30.8 ± 4.3c</td>
<td>27.3 ± 2.6c</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>20.52 ± 3.4c</td>
<td>94.51 ± 30.4c</td>
<td>90.94 ± 33.2c</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td>3.17 ± 1.9c</td>
<td>45.57 ± 8.4c</td>
<td>39.88 ± 13.8c</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Total lipid accumulation (fluorescence/μg protein)</td>
<td>160.3 ± 32.2c</td>
<td>2921 ± 769.9c</td>
<td>2123 ± 576c</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

*P < 0.05 is considered significant, different letters indicate a significant difference between groups. Variables expressed by mean ± SD. LOLA: Ornithine aspartate; MASLD: Metabolic-dysfunction associated steatotic liver disease.

Figure 1 Alpha diversity analysis according to different metrics. A: Observed; B: ACE; C: Shannon. Statistical confidence was accessed using the multivariate Kruskal-Wallis test. *P-value < 0.05. MASLD: Metabolic-dysfunction associated steatotic liver disease; LOLA: Ornithine aspartate.

with LOLA was not able to restore its levels.

### DISCUSSION

In this study, we demonstrated that LOLA may induce changes in bacterial composition and metabolic pathways in a nutritional rat model of MASLD, that mirrors human disease. It is noteworthy that in a previous study conducted by our research team using this experimental model, histopathological analysis revealed that subjects treated with HFCD exhibited a predominant occurrence of microvesicular steatosis, in conjunction with moderate macrovesicular steatosis. These findings were accompanied by minimal signs of inflammatory activity and occasional fibrosis. Furthermore, improvements were observed in liver disease parameters (biochemistry, collagen deposition, miRNAs) and cardiovascular health (systemic inflammation and cardiomyocyte integrity)[9-11].

Butterworth and Canbay suggest that LOLA can induce beneficial effects on MASLD based not only on decreasing ammonia, but also through its transformation in L-glutamine, L-arginine, and glutathione. However, as the evidence is scarce, LOLA is not used in MASLD[4,20]. So far, only a recent work analyzed microbiota changes at LOLA treatment. Horvath et al[21], 2022, evaluated the microbiota composition of 15 cirrhotic patients treated or not treated with LOLA. The authors reported no differences in alpha and beta diversities, but significant differential abundances in two genera (*i.e.*, Flavonifractor and Oscilospira) were found in patients treated with LOLA. It is important to emphasize that cirrhosis itself can induce several important changes in gut microbiota[22,23]. Our study also did not show any difference in alpha and beta diversities comparing LOLA to MASLD.

However, in the present study, 22 OTUs were differentially abundant among groups; among them, only 3 differed between LOLA and MASLD, namely: *Helicobacter rodentium*, *Parabacteroides goldsteinii*, and *Parabacteroides distasonis*. The other OTUs showed an increase (10 OTUs) or decrease (9 OTUs) in control when compared to both intervention groups (MASLD and LOLA), but no significant differentiation was observed between MASLD and LOLA. Among the 3 OTUs that differed between MASLD and LOLA, the development of the disease only caused a reduction in the relative abundance of *Helicobacter rodentium*, a normal colonizer of the gastrointestinal tract of rats, while LOLA intervention restored its abundance to the control levels. A possible hypothesis is that *Helicobacter rodentium* could be benefited from the presence of macromolecules, such as amino acids, as a source of nitrogen for metabolic pathways, increasing its...
Figure 2 Beta diversity analysis using principal coordinates analysis and dendrogram clustering to evaluate similarities and differences among bacterial community structures. A: Principal coordinate analysis of bacterial community structures based on the Bray-Curtis distance metric; B: Hierarchical clustering dendrogram based on the Bray-Curtis dissimilarity index. Samples were colored according to the experimental group: Control, metabolic-dysfunction associated steatotic liver disease, and ornithine aspartate. Statistical confidence for the sample grouping was accessed using analysis of similarities. MASLD: Metabolic-dysfunction associated steatotic liver disease; LOLA: Ornithine aspartate.

Figure 3 Differential abundant operational taxonomic units between ornithine aspartate and metabolic-dysfunction associated steatotic liver disease by Lefse. Statistical confidence was assessed using the Kruskal-Wallis test. Taxa were ranked by linear discriminant analysis (LDA) score. Differences were considered significant for a logarithmic LDA score threshold of ±2.0 and P-value < 0.05. MASLD: Metabolic-dysfunction associated steatotic liver disease; LOLA: Ornithine aspartate.

abundance with LOLA intervention and restoring it to control levels[24]. Interestingly, Parabacteroides goldsteinii and Parabacteroides distasonis are two species recently identified as candidates for next-generation probiotics due to its beneficial effects in preventing and treating inflammation and obesity[25,26]. The mechanisms by which these probiotics act may be related to a reduction in adipocyte hypertrophy, recovery of gene expression involved in lipid transport, lipogenesis, and β-oxidation in the liver in addition to maintaining intestinal integrity, inducing thermogenesis, and reducing endotoxemia and inflammation, thus preserving intestinal homeostasis and improve gut barrier functions in vivo[27]. Taken together, the findings suggest that LOLA may act in MASLD by secondary mechanisms, affecting specific probiotic microbes and attenuating inflammation and fat accumulation.

The functional prediction provided two different metabolic profiles between MASLD and LOLA. In MASLD, the change in energy source is evidenced by the acetylene degradation and glycogen biosynthesis, which indicates that acetylene is been used as a source of carbon and energy (characteristic of anaerobes) while glucose metabolism has been suppressed and stored in glycogen. Thiazole biosynthesis, which synthesizes the precursor of thiamine (vitamin B1), is related to the storage of glucose in glycogen because thiamine is able to decrease hyperglycemia and increase the glycogen content[28]. The nucleotide degradation and deoxyribonucleotide biosynthesis is another interesting metabolic feature of MASLD involving nucleotide recycling because deoxyribonucleotides are obtained by the reduction of ribose
already incorporated into nucleotides. On this matter, the L-glutamate and L-glutamine biosynthesis pathway may have an important role as L-glutamate is at the crossroads of amino acid metabolism[29], where it can donate its amino group for new amino acid synthesis or can lose the amino group via deamination to 2-oxoglutarate.

Altogether, our results indicate that the bacterial and metabolic differences in LOLA treatment are related to L-aspartate, while no differences in microbial pathways related to L-ornithine were observed when comparing LOLA and MASLD. This contrasting effect of LOLA components on the gut microbiota may be explained by the pharmacokinetic and pharmacodynamic properties of the drug[30]. As orally administered, LOLA promptly dissociates into its component amino acids L-ornithine and L-aspartate in the duodenum, which are absorbed from the small intestine by active transport across the brush border of the intestinal epithelium. Most of the aspartate is metabolized in the intestine, and the remaining serves primarily for glutamine synthesis in the liver, muscles, and brain[31]. On the other hand, L-ornithine may be quickly absorbed by the epithelium cells and, after reaching the portal blood, it is directly taken up by the periportal hepatocytes of the liver and metabolized by the mitochondria where it serves as an intermediary in the urea cycle and is an activator of carbamyl-phosphate synthetase, the rate-limiting enzyme of urea synthesis[32]. In summary, this means that, after being absorbed, L-aspartate is reabsorbed and available in the gut where it can also be used by some microorganisms, while L-ornithine is quickly absorbed and taken up to the liver. This fast absorption of L-ornithine does not leave time for microbial usage, which also explains why LOLA does not restore the elevated gut microbial urea cycle metabolism observed in MASLD.

CONCLUSION

In conclusion, although LOLA had no influence on alpha and beta diversity in this nutritional model of MASLD, it was associated with changes in specific probiotic members of the gut microbiota and their related metabolic pathways. In addition, our results indicate that the bacterial and metabolic differences in LOLA treatment are related to L-aspartate, while no differences in microbial pathways related to L-ornithine were observed when comparing LOLA and MASLD. Finally, the composition and functional prediction of the microbiota observed in our work could be complemented with metagenomics sequencing and metabolomics analysis in future studies.
ARTICLE HIGHLIGHTS

Research background
There are scarce evidence of ornithine aspartate (LOLA) usefulness in metabolic-dysfunction associated steatotic liver disease (MASLD). Since LOLA comes into direct contact with the intestinal tract upon oral administration, it could interact with the intestinal microbiota. This study analyzed LOLA’s influence on gut microbiota (GM) in an experimental model of MASLD.

Research motivation
Considering GM emerging role in the development of MASLD and the significant role of amino acids in the protection and function of the intestinal barrier, we decided to investigate LOLA’s role on GM for a better understanding of the factors and molecular mechanisms involved in the pathophysiology of the disease.

Research objectives
To evaluate the diversity, structure and composition of the intestinal microbiota and identify which microbiota taxa are related to MASLD and LOLA, as well as identify and analyze the predicted metabolic pathways of the microbiota in an experimental model of MASLD with or without LOLA treatment.

Research methods
Adult male Sprague Dawley rats were randomized into three groups: Control (10 rats fed with a standard diet), MASLD (10 rats fed with a high-fat and choline-deficient diet), and LOLA (10 rats receiving 200 mg/kg/d LOLA, after the 16th week receiving high-fat and choline-deficient diet). After 28 wk of the experiment, animals were euthanized and feces present in the intestine were collected. After fecal DNA extraction, the V4 region of the 16S rRNA gene was amplified followed by sequencing in an Ion S5™ system.

Research results
Alpha and beta diversity metrics were comparable between MASLD and LOLA. 3 OTUs were differentially abundant.
between MASLD and LOLA, which belong to the species *Helicobacter rodentium*, *Parabacteroides goldsteinii*, and *Parabacteroides distasonis*. The functional prediction provided two different metabolic profiles between MASLD and LOLA. The 9 pathways differentially abundant in MASLD are related to a change in energy source, adenosine/purine nucleotides degradation as well as guanosine and adenosine deoxyribonucleotides biosynthesis. The 14 pathways differentially abundant in LOLA are associated with four major metabolic functions primarily influenced by L-aspartate, including tricarboxylic acid cycle pathways, purine/guanosine nucleotides biosynthesis, pyrimidine ribonucleotides biosynthesis and salvage as well as lipid IVA biosynthesis.

**Research conclusions**

Although LOLA had no influence on alpha and beta diversity in this nutritional model of MASLD, it was associated with changes in specific gut microbes and their related metabolic pathways.

**Research perspectives**

Metabolomic and metagenomic sequencing analyzes in future studies, as well as a detailed evaluation of the probiotics found and their prophylactic use in MASLD are needed.

---

### FOOTNOTES

**Author contributions:** Lange EC and Rampelotto PH contributed equally to this work; Lange EC, Rampelotto PH and Alvares-da-Silva MR performed the conceptualization, methodology, formal analysis, writing – original draft preparation, and writing – review & editing; Longo L, Freitas LBR, Uribe-Cruz C performed methodology and writing – original draft preparation.

**Supported by** Financiamento e Incentivo à Pesquisa from Hospital de Clínicas de Porto Alegre (FIPe/HCPA), No. 2020-0037; Coordination for the Improvement of Higher Education Personnel, CAPES/PNPD; and the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).

**Institutional animal care and use committee statement:** All experimental procedures were approved by the Ethics Committee for the Use of Animals protocol No. 2020-0037, in accordance with international guidelines for animal welfare and measures were taken to minimize animal pain and discomfort.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Data sharing statement:** He raw data of high-throughput sequencing is available at the NCBI GenBank Sequence Read Archive (SRA) under accession number PRJNA898069.

**ARRIVE guidelines statement:** The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Country/Territory of origin:** Brazil

**ORCID number:** Elisa Carolina Lange 0000-0002-9612-9065; Pablo Henrique Rampelotto 0000-0002-8992-9697; Larisse Longo 0000-0002-4453-7227; Laura Bany Rodrigues de Freitas 0000-0002-7571-2980; Carolina Uribe-Cruz 0000-0002-0526-3067; Mario Reis Alvares-da-Silva 0000-0002-5001-246X.

**S-Editor:** Gong ZM

**L-Editor:** A

**P-Editor:** Cai YX

---

### REFERENCES


Biol Res development of experimental fatty liver driven by overnutrition. DOI: 10.1128/AEM.01541-09

Patients With Cirrhosis. DOI: 10.1159/000491429


Lange EC et al. LOLA effects on gut microbiota